Navigation Links
First Live U.S. Demonstration of Cellvizio GI In Vivo Cellular Imaging Technology to Occur at Johns Hopkins Conference

PHILADELPHIA, March 5 /PRNewswire/ -- Cellvizio Inc., a leader in in vivo cellular imaging, announced today that the first live U.S. demonstration of its Cellvizio(R) GI technology will be conducted March 10, 2008, during the Johns Hopkins University School of Medicine's Eighth Annual Gastroenterology and Hepatology Viva La Vida Conference.

Cellvizio Inc. is the U.S. subsidiary of Paris-based Mauna Kea Technologies and develops and markets Cellvizio, a fundamentally new endoscopic imaging approach which could improve patient care by eliminating the need for unnecessary biopsies and could enhance the diagnosis of a broad range of diseases via in vivo cellular imaging.

The Cellvizio GI procedure will be performed at the Johns Hopkins Hospital in Baltimore during an endoscopy to assist with the diagnosis of Barrett's esophagus. It will be seen live via satellite by attendees of the conference, which is being held March 10-15 in San Juan, Puerto Rico. Gastroenterologists, surgeons and other healthcare professionals with an interest in gastroenterology and hepatology are participating in the program.

"Cellvizio allows physicians to view live tissue inside the body at the cellular level in real-time with a miniaturized microscope threaded through an endoscope and has the potential to benefit patients by reducing invasiveness while speeding up diagnosis," explained Sacha Loiseau, president, CEO and founder of Mauna Kea Technologies. "For example, a current diagnosis of Barrett's esophagus may require 10 to 50 biopsies to be taken and analyzed by a pathologist off line. The use of Cellvizio during this procedure could help reduce this number significantly by allowing physicians to avoid unnecessary biopsies."

Cellvizio GI is commercially available in Europe and in the United States.

About Mauna Kea Technologies:

Mauna Kea Technologies leads the growing in vivo cellular imaging market enabling physicians to visualize, diagnose and treat pathologies that can not be seen using other imaging techniques. Mauna Kea Technologies' flagship Cellvizio system provides microscopic visualization of mucosal tissue and promises to improve clinical outcomes by increasing the diagnostic yield of existing endoscopic procedures. With over 1000 Cellvizio procedures completed to date, Mauna Kea Technologies is currently focused on the gastroenterology and pulmonology markets. The company plans to expand into other markets in the future. The company also has a distribution agreement with Leica Microsystems to sell products for the Small Animal Imaging market in Europe, the U.S. and Japan. For more information about Mauna Kea Technologies:

About The Conference:

The Eighth Annual Gastroenterology and Hepatology: Viva la Vida conference will provide, through formal lectures, followed by questions and answers, a discussion of various disorders, with an emphasis on recent developments. Participants will be updated on the latest management of GI cancers and approaches for the difficult GI bleeder. Endoscopic imaging and therapies will be demonstrated live from the Johns Hopkins Hospital and University of Puerto Rico by renowned international experts.
For more information:


Erich Sandoval

Lazar Partners

Tel. 212-867-1773


SOURCE Cellvizio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
2. Enerkem announces progress on construction of Canadas first cellulosic ethanol plant
3. Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product
4. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
5. BSPs New Line of HyperQ Products: Bedside Ischemia Monitoring Systems Announces Successful Results of First Feasibility Study
6. First Complete Career Service for Life-Science Professionals
7. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
8. Biopure Announces 2008 First Quarter Financial Results
9. Addrenex Pharmaceuticals Reaches Milestone with Filing of NDA for First Product, CloniBID, to Treat Hypertension
10. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
11. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
Post Your Comments:
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
(Date:6/23/2016)... India , June 23, 2016 ... media market research report to its pharmaceuticals section ... profiles, product details and much more. ... spread across 151 pages, profiling 15 companies and ... available at . ...
Breaking Biology Technology:
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
Breaking Biology News(10 mins):